Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. - Alba, E; Albanell, J; de la Haba, J; Barnadas, A; Calvo, L; Sánchez-Rovira, P; Ramos, M; Rojo, F; Burgués, O; Carrasco, E; Caballero, R; Porras, I; et al. (British Journal of Cancer, 2014)